Research Article: TMED9: a potential therapeutic target and prognostic marker in glioma and its implications across pan-cancer contexts
Abstract:
Background: The escalating global cancer burden, projected to reach 35 million new cases by 2050, underscores the urgent need for innovative cancer biomarkers to improve treatment efficacy and patient outcomes. The TMED family, particularly TMED9, has garnered attention for its involvement in cancer progression; however, its comprehensive role across various cancer types remains poorly understood.
No summary available.